Franck Baylé

1.2k total citations
28 papers, 664 citations indexed

About

Franck Baylé is a scholar working on Psychiatry and Mental health, Cellular and Molecular Neuroscience and Clinical Psychology. According to data from OpenAlex, Franck Baylé has authored 28 papers receiving a total of 664 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Psychiatry and Mental health, 7 papers in Cellular and Molecular Neuroscience and 6 papers in Clinical Psychology. Recurrent topics in Franck Baylé's work include Schizophrenia research and treatment (15 papers), Bipolar Disorder and Treatment (9 papers) and Neurotransmitter Receptor Influence on Behavior (7 papers). Franck Baylé is often cited by papers focused on Schizophrenia research and treatment (15 papers), Bipolar Disorder and Treatment (9 papers) and Neurotransmitter Receptor Influence on Behavior (7 papers). Franck Baylé collaborates with scholars based in France, United States and United Kingdom. Franck Baylé's co-authors include D. Misdrahi, Pierre‐Michel Llorca, Emmanuelle Corruble, Philip Gorwood, Bruno Millet, Marie‐France Poirier, Jean‐Pierre Olié, Marie‐Chantal Bourdel, Amine Benyamina and Bruno Falissard and has published in prestigious journals such as Scientific Reports, Biochemical Pharmacology and Journal of Affective Disorders.

In The Last Decade

Franck Baylé

27 papers receiving 631 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Franck Baylé France 14 325 198 124 115 94 28 664
José Antonio Monreal Spain 17 349 1.1× 241 1.2× 95 0.8× 75 0.7× 59 0.6× 84 917
Manuel Arrojo Spain 18 300 0.9× 227 1.1× 79 0.6× 117 1.0× 84 0.9× 64 821
Camilla Bock Denmark 13 193 0.6× 227 1.1× 114 0.9× 78 0.7× 122 1.3× 15 696
Alain Dervaux France 13 328 1.0× 200 1.0× 70 0.6× 84 0.7× 152 1.6× 64 662
Umberto Micò Italy 13 347 1.1× 242 1.2× 83 0.7× 93 0.8× 100 1.1× 21 584
Sjacko Sobczak Netherlands 12 296 0.9× 259 1.3× 107 0.9× 160 1.4× 112 1.2× 45 851
Thomas Bronisch Germany 14 196 0.6× 410 2.1× 101 0.8× 95 0.8× 70 0.7× 36 802
Anna Mané Spain 18 583 1.8× 149 0.8× 120 1.0× 222 1.9× 106 1.1× 70 902
Rebecca Schennach Germany 20 458 1.4× 285 1.4× 138 1.1× 95 0.8× 102 1.1× 37 830
Sirijit Suttajit Thailand 16 371 1.1× 155 0.8× 121 1.0× 102 0.9× 138 1.5× 42 682

Countries citing papers authored by Franck Baylé

Since Specialization
Citations

This map shows the geographic impact of Franck Baylé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franck Baylé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franck Baylé more than expected).

Fields of papers citing papers by Franck Baylé

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franck Baylé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franck Baylé. The network helps show where Franck Baylé may publish in the future.

Co-authorship network of co-authors of Franck Baylé

This figure shows the co-authorship network connecting the top 25 collaborators of Franck Baylé. A scholar is included among the top collaborators of Franck Baylé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franck Baylé. Franck Baylé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sibéoni, Jordan, Émilie Manolios, Franck Baylé, et al.. (2023). Perspectives of French adolescents with ADHD and child and adolescent psychiatrists regarding methylphenidate use. Scientific Reports. 13(1). 4040–4040. 2 indexed citations
2.
Tessier, A., Laurent Boyer, Mathilde M. Husky, et al.. (2017). Medication adherence in schizophrenia: The role of insight, therapeutic alliance and perceived trauma associated with psychiatric care. Psychiatry Research. 257. 315–321. 46 indexed citations
3.
4.
5.
Courtet, Philippe, Guillaume Vaïva, Emmanuelle Corruble, et al.. (2015). The ability of early changes in motivation to predict later antidepressant treatment response. Neuropsychiatric Disease and Treatment. 11. 2875–2875. 14 indexed citations
6.
Gorwood, Philip, et al.. (2015). An increase in joy after two weeks is more specific of later antidepressant response than a decrease in sadness. Journal of Affective Disorders. 185. 97–103. 10 indexed citations
7.
Gorwood, Philip, Franck Baylé, Guillaume Vaïva, et al.. (2013). Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis. European Psychiatry. 28(6). 362–371. 26 indexed citations
8.
Baylé, Franck, et al.. (2012). Mechanisms of insight in schizophrenia and impact of cognitive remediation therapy. Comprehensive Psychiatry. 54(4). 369–380. 35 indexed citations
9.
Misdrahi, D., et al.. (2011). The influence of therapeutic alliance and insight on medication adherence in schizophrenia. Nordic Journal of Psychiatry. 66(1). 49–54. 60 indexed citations
10.
Llorca, Pierre‐Michel, Philippe Courtet, Mocrane Abbar, et al.. (2010). Dépistage et prise en charge du trouble bipolaire : Résultats. L Encéphale. 36. S86–S102. 26 indexed citations
11.
Napryeyenko, Oleksandr, Guadalupe Martínez, Tsvi Fischel, et al.. (2010). EFFICACY AND TOLERABILITY AMONG PATIENTS WITH RECENT ONSET SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG-ACTING INJECTABLE (RLAI). Schizophrenia Research. 117(2-3). 496–496. 1 indexed citations
12.
Misdrahi, D., Hélène Verdoux, Christophe Lançon, & Franck Baylé. (2008). The 4-Point ordinal Alliance Self-report: a self-report questionnaire for assessing therapeutic relationships in routine mental health. Comprehensive Psychiatry. 50(2). 181–185. 32 indexed citations
13.
Kasper, Siegfried, et al.. (2008). P.2.c.022 Superior antidepressant efficacy of agomelatine versus sertraline: a randomised, double-blind study. European Neuropsychopharmacology. 18. S336–S337. 3 indexed citations
14.
Arbus, Christophe, Amine Benyamina, Pierre‐Michel Llorca, et al.. (2007). Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. European Journal of Pharmaceutical Sciences. 32(4-5). 357–366. 10 indexed citations
15.
Baylé, Franck, et al.. (2004). [A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression].. PubMed. 29(4 Pt 1). 322–8. 4 indexed citations
16.
Corruble, Emmanuelle, Amine Benyamina, Franck Baylé, Bruno Falissard, & Patrick Hardy. (2003). Understanding impulsivity in severe depression? A psychometrical contribution. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 27(5). 829–833. 87 indexed citations
17.
Hameg, Ahcène, Franck Baylé, Philippe Nuss, et al.. (2003). Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochemical Pharmacology. 65(3). 435–440. 25 indexed citations
18.
Daban, Claire, Isabelle Amado, Franck Baylé, et al.. (2002). Correlation between clinical syndromes and neuropsychological tasks in unmedicated patients with recent onset schizophrenia. Psychiatry Research. 113(1-2). 83–92. 34 indexed citations
19.
Poirier, Marie‐France, Franck Baylé, Bruno Millet, et al.. (2002). Prevalence of smoking in psychiatric patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 26(3). 529–537. 123 indexed citations
20.
Álvarez-Guerra, Miriam, Ahcène Hameg, Franck Baylé, Michel Dib, & Ricardo P. Garay. (2002). 5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle. European Journal of Pharmacology. 454(2-3). 235–239. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José Antonio Monreal Breakdown of academic impact, for papers by Manuel Arrojo Breakdown of academic impact, for papers by Camilla Bock Breakdown of academic impact, for papers by Alain Dervaux Breakdown of academic impact, for papers by Umberto Micò Breakdown of academic impact, for papers by Sjacko Sobczak Breakdown of academic impact, for papers by Thomas Bronisch Breakdown of academic impact, for papers by Anna Mané Breakdown of academic impact, for papers by Rebecca Schennach Breakdown of academic impact, for papers by Sirijit Suttajit
Rankless by CCL
2026